Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.21873/invivo.12134 http://scihub22266oqcxt.onion/10.21873/invivo.12134 32871846!7652439!32871846     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       In+Vivo 2020 ; 34 (5): 3023-3026 Nephropedia Template TP {{tp|p=32871846|t=2020. Ivermectin Docks to the SARS-CoV-2 Spike Receptor-binding Domain Attached to ACE2 |pdf=|usr=}}{{32871846}} gab.com Text Ivermectin Docks to the SARS-CoV-2 Spike Receptor-binding Domain Attached to ACE2 JO: In Vivo http://www.kidney.de/pget.php?&tw=1&pmid=32871846 #FOAvip BACKGROUND/AIM: Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). One drug that has attracted interest is the antiparasitic compound ivermectin, a macrocyclic lactone derived from the bacterium Streptomyces avermitilis. We carried out a docking study to determine if ivermectin might be able to attach to the SARS-CoV-2 spike receptor-binding domain bound with ACE2. MATERIALS AND METHODS: We used the program AutoDock Vina Extended to perform the docking study. RESULTS: Ivermectin docked in the region of leucine 91 of the spike and histidine 378 of the ACE2 receptor. The binding energy of ivermectin to the spike-ACE2 complex was -18 kcal/mol and binding constant was 5.8 e-08. CONCLUSION: The ivermectin docking we identified may interfere with the attachment of the spike to the human cell membrane. Clinical trials now underway should determine whether ivermectin is an effective treatment for SARS-Cov2 infection. Twit Text FOAVip Ivermectin Docks to the SARS-CoV-2 Spike Receptor-binding Domain Attached to ACE2 ????In Vivo http://www.kidney.de/pget.php?&tw=1&pmid=32871846 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32871846 #FOAvip English Wikipedia <ref>{{Cite pmid|32871846}}</ref> Ivermectin Docks to the SARS-CoV-2 Spike Receptor-binding Domain Attached to ACE2 #MMPMID32871846 Lehrer S; Rheinstein PH In Vivo 2020[Sep]; 34 (5): 3023-3026 PMID32871846show ga BACKGROUND/AIM: Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). One drug that has attracted interest is the antiparasitic compound ivermectin, a macrocyclic lactone derived from the bacterium Streptomyces avermitilis. We carried out a docking study to determine if ivermectin might be able to attach to the SARS-CoV-2 spike receptor-binding domain bound with ACE2. MATERIALS AND METHODS: We used the program AutoDock Vina Extended to perform the docking study. RESULTS: Ivermectin docked in the region of leucine 91 of the spike and histidine 378 of the ACE2 receptor. The binding energy of ivermectin to the spike-ACE2 complex was -18 kcal/mol and binding constant was 5.8 e-08. CONCLUSION: The ivermectin docking we identified may interfere with the attachment of the spike to the human cell membrane. Clinical trials now underway should determine whether ivermectin is an effective treatment for SARS-Cov2 infection. |Angiotensin-Converting Enzyme 2[MESH] |Betacoronavirus/chemistry/*drug effects/pathogenicity[MESH] |Binding Sites/drug effects[MESH] |COVID-19[MESH] |Cell Membrane/drug effects[MESH] |Coronavirus Infections/*drug therapy/virology[MESH] |Drug Repositioning[MESH] |Histidine/chemistry[MESH] |Humans[MESH] |Ivermectin/*chemistry/therapeutic use[MESH] |Leucine/chemistry[MESH] |Molecular Docking Simulation[MESH] |Pandemics[MESH] |Peptidyl-Dipeptidase A/*chemistry/drug effects[MESH] |Pneumonia, Viral/*drug therapy/virology[MESH] |SARS-CoV-2[MESH]Ivermectin Docks to the SARS-CoV-2 Spike Receptor-binding Domain Attac(epmc).pdf DeepDyve Pubget Overpricing